AtriCure, Inc.ATRCEarnings & Financial Report
Nasdaq · Health Care · Surgical & Medical Instruments & Apparatus
AtriCure, Inc. is a global medical device company specializing in the research, development, and manufacturing of innovative surgical tools and therapeutic solutions for treating atrial fibrillation and associated cardiac conditions. Its core customers include hospitals, cardiac surgery centers, and healthcare providers across North America, Europe, and the Asia Pacific region, with products designed to support safer, more effective minimally invasive cardiac procedures.
Top Holders
| Holder | % Owned | Shares | Change | As of |
|---|---|---|---|---|
| The Vanguard Group | 10.06% | 4.8M | ▲ +0.05pp | 2024-02-13 |
| BlackRock, Inc. | 8.80% | 4.2M | — | 2024-01-25 |
| OF ABOVE PERSONS | 7.20% | 3.4M | ▲ +4.70pp | 2024-02-14 |
| NOS. OF ABOVE PERSONS | 5.81% | 2.8M | — | 2024-11-14 |
Insider Transactions
Net 90d: −$149.2K · buys $0 / sells $149.2KRange:
Action:
Role:
| Insider | Role | Action | ||||
|---|---|---|---|---|---|---|
| 2026-03-12 | Vinayak Doraiswamy | Chief Scientific Officer | Sell (open market) | 5.0K | $29.83 | $149.2K |
| 2026-03-10 | WHITE ROBERT S. | Director | Option exercise | 10.0K | $14.99 | $149.9K |
| 2026-03-06 | CARREL MICHAEL H | President, CEO, & Director | Gift | 5.0K | $0.00 | $0 |
| 2026-03-06 | CARREL MICHAEL H | President, CEO, & Director | Gift | 1.0K | $0.00 | $0 |
| 2026-03-01 | Salvatore Privitera | Chief Technical Officer | Grant | 30.4K | $0.00 | $0 |
| 2026-03-01 | Salvatore Privitera | Chief Technical Officer | Grant | 15.2K | $0.00 | $0 |
| 2026-03-01 | Noznesky Justin J | Chief Mktg & Strategy Officer | Grant | 28.0K | $0.00 | $0 |
| 2026-03-01 | Noznesky Justin J | Chief Mktg & Strategy Officer | Grant | 15.2K | $0.00 | $0 |
| 2026-03-01 | CARREL MICHAEL H | President, CEO, & Director | Grant | 68.6K | $0.00 | $0 |
| 2026-03-01 | CARREL MICHAEL H | President, CEO, & Director | Grant | 101.3K | $0.00 | $0 |
1–10 of 18
Page 1 / 2